STORM Therapeutics is a clinical-stage biotech headquartered in Cambridge, UK, led by CEO Jerry McMahon. Its lead candidate, STC-15, is an oral small-molecule inhibitor of METTL3 and is described as the first RNA‑modifying enzyme inhibitor to enter human clinical trials. STC-15 is currently being assessed as a monotherapy in a Phase 2 study for selected sarcoma indications, and the company has reported dosing the first patient in that study. In April 2026 STORM raised $56M in a Series C to support advancement of STC-15 and to enhance the Phase 2 program. The company’s core focus is developing therapies that target RNA modifications to reprogram malignant cells.

Total raised

$125M

Funding rounds

5

Latest round

Series C

Latest activity

Apr 2026